Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.65 |
| ▸ | CA1 | P00915 | 4/20 | 0.65 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL697052 | 1.00 | CA2 (0.65) | CA2CA1CASP3GAAMAPT | |
| SCHEMBL712931 | 1.00 | CA2 (0.65) | CA2CA1CASP3GAAMAPT | |
| SCHEMBL29159682 | 0.98 | CA2 (0.63) | CA2CA1CASP3GAAMAPT | |
| SCHEMBL28334970 | 0.86 | CA2 (0.50) | CA2CA1ACEPTPN1SLC1A2 | |
| SCHEMBL9829896 | 0.86 | CA2 (0.66) | CA2CA1CASP3PTPN1TMPRSS15 | |
| SCHEMBL5280601 | 0.86 | CA2 (0.68) | CA2CA1ACEPTPN1SLC1A2 | |
| SCHEMBL9829891 | 0.86 | CA2 (0.66) | CA2CA1CASP3PTPN1TMPRSS15 | |
| SCHEMBL5191250 | 0.86 | CA2 (0.68) | CA2CA1ACEPTPN1SLC1A2 | |
| Phenylalanine SCHEMBL10413087 | 0.85 | SLC7A5 (0.59) | CA2CA1GAAMAPTACE | |
| SCHEMBL20875154 | 0.84 | CTSL (0.50) | CA2CA1CASP3GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016116076-A1 | NEW POSSIBILITIES OF CHIRAL RESOLUTION OF BEDAQUILINE | ZENTIVA, K.S. (CZ) | 2016-07-28 | — | — | WO | claimed |
| US-20070112216-A1 | Method for producing chiral mercapto amino acids | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2007-05-17 | — | — | US | claimed |
| EP-1457487-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CIS-PIPERIDINE DERIVATIVES | Toray Fine Chemicals Co., Ltd. (JP) | 2004-09-15 | — | — | EP | claimed |
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN, (JP) | 2004-09-02 | — | — | US | claimed |
| US-4213784-A | Process for producing heat developable light-sensitive compositions and elements | FUJI PHOTO FILM CO., LTD. (JP) | 1980-07-22 | — | — | US | claimed |
| US-20240252693-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | NOVARTIS PHARMACEUTICALS CORPORATION | 2024-08-01 | — | — | US | disclosed |
| EP-4323017-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | Novartis AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| CN-117083088-A | Folate receptor targeted radiotherapy agent and use thereof | 诺华股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-11607421-B2 | Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof | METANOI THERAPEUTICS, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| CN-115666542-A | Ethanolamine formulations for the treatment of epithelial ovarian cancer | 梅塔诺伊治疗公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2022219569-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | NOVARTIS AG (CH) | 2022-10-20 | — | — | WO | disclosed |
| EP-3781151-A1 | BAMBUTEROL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Université de Caen Normandie (FR) | 2021-02-24 | — | — | EP | disclosed |
| EP-0439585-A1 | IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS. | EPIPHARM ALLERGIE SERVICE (AT) | 1991-08-07 | — | — | EP | disclosed |
| WO-1991002768-A1 | IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS | EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) | 1991-03-07 | — | — | WO | disclosed |
| US-4935355-A | USING PROTEASE TO COUPLE AMINO ACIDS IN PRESENCE OF POLYOL; BY-PRODUCT INHIBITION | SYNTHETECH, INC. (US) | 1990-06-19 | — | — | US | disclosed |
| EP-0132373-B1 | A NEUTRAL AMINO ACID COMPLEX AND A METHOD FOR OPTICAL RESOLUTION OF A DL-AMINO ACID | AJINOMOTO CO., INC. (JP) | 1988-10-05 | — | — | EP | disclosed |
| EP-0239362-A2 | Anti-tumor agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-09-30 | — | — | EP | disclosed |
| US-4610827-A | Amino acid complex and a method for optical resolution of a DL-amino acid | AJINOMOTO CO., INC. (JP) | 1986-09-09 | — | — | US | disclosed |
| EP-0132373-A1 | A neutral amino acid complex and a method for optical resolution of a DL-amino acid | AJINOMOTO CO., INC. (JP) | 1985-01-30 | — | — | EP | disclosed |
| US-4213784-A | Process for producing heat developable light-sensitive compositions and elements | FUJI PHOTO FILM CO., LTD. (JP) | 1980-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TYR, DDC, TARBP1 | CA2 2307/4885CA1 2106/4885CASP3 1983/4885 |
| US-11607421-B2 | Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof | PHOSPHO1, SGMS2, CHKB | CA2 4410/4885CA1 3038/4885CASP3 2702/4885 |
| US-20240252693-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | FOLR1, FOLR2, FOLH1 | CA2 4271/4885CA1 2437/4885CASP3 3333/4885 |
| US-20070112216-A1 | Method for producing chiral mercapto amino acids | CPN1, AKR1C3, AHCY | CA2 361/4885CA1 113/4885CASP3 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.